New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis

Álvarez-Fernández, Indira; Prieto, Belén; Rodríguez, Verónica; Ruano, Yolanda; Escudero, Ana I; Álvarez, Francisco V.

doi:10.1515/cclm-2013-0901

Cited by 57 publications

(61 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

“…5,51,75 Both the PELICAN study on the Triage PlGF test 5 and the PROGNOSIS study on the Elecsys sFlt-1 to PlGF ratio test 51 included women in the UK, although in the PROGNOSIS study only 1 of the 30 study centres was in the UK, with 76 UK participants represented among 1050 total participants. The remaining study by Álvarez-Fernández et al 75 was not conducted in the UK. Two of the studies were of a single-cohort design, whereas the PROGNOSIS study 51 had two cohorts: a 'development' cohort to derive a cut-off value-based prediction model for the sFlt-1 to PlGF ratio (n = 500) and a 'validation' cohort to test the model (n = 550).…”

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

“…Two of the studies recruited patients prospectively 5,51 and one retrospectively. 75 The major studies, PELICAN 5 and PROGNOSIS, 51 had relatively large sample sizes for those gestational age groups that are relevant to the current diagnostic assessment, analysing 424-1050 patients. All the studies covered the majority of the period of pregnancy specified in the NICE scope (20 +0 to 36 +6 weeks, i.e.…”

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

“…Groups of women who presented with fetuses at gestational ages exceeding those specified in the NICE scope (i.e. after 36 +6 weeks) were reported in two studies; 5,75 these groups are not considered in the current review.…”

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

“…) and the Elecsys sFlt-1 to PlGF ratio test product insert 46 l a study by Álvarez-Fernández et al reported in an academic journal paper 75 and a meeting abstract 76 (the EAG contacted the authors of this study to confirm that it met the eligibility criteria).…”

mentioning

confidence: 97%

See 4 more Smart Citations

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Frampton

Jones

Rose

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess 2016;20(87).Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch ® ) and Current Contents ® / Clinical Medicine. This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment NICE TAR and DAREditorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 14/69/05. The protocol was agreed in March 2015. The assessment report began editorial review in September 2015 and was accepted for publication in June 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The ...

show abstract

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

Section: General Characteristics Of the Study Participantsmentioning

confidence: 99%

mentioning

confidence: 97%

See 3 more Smart Citations

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Frampton

Jones

Rose

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

show abstract

Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants

Heazell

Hayes

Whitworth

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Impact of IL‐22 and IL‐22 receptor alpha 1 polymorphisms on preeclampsia risk in Chinese Han women

Niu¹,

Zhao²,

Liu³

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Previous studies have indicated that an increased inflammatory response plays an important role in preeclampsia (PE), and rising levels of interleukin (IL)-22 can trigger inflammation and hyperproliferation, leading to increased production of several pro-inflammatory cytokines such as IL-1, IL-6, and IL-8. We aimed to investigate the association between polymorphisms of IL-22 and IL-22 receptor alpha 1 gene (IL-22RA1) and PE in Chinese Han population. Single nucleotide polymorphisms (SNPs) rs2227485 in IL-22 and rs3795299 in IL-22RA were genotyped by Taqman real-time PCR in 1071 PE patients and 1263 control subjects. Differences in genetic distribution were compared between two groups using the chi-square test. Significant differences were observed in genotypic and allelic frequencies of IL-22RA1 rs3795299 between healthy controls and PE patients (P < 0.001 by genotype; P = 0.001, odds ratio = 1.253, 95% confidence interval 1.103-1.424 by allele). There were also significant differences in genotypic and allelic frequencies of rs3795299 between late-onset/mild PE and control groups. In addition, we found obvious statistic difference for the allele of early-onset PE/the genotype of late-onset PE and control subgroups for IL-22 rs2227485. IL-22 rs2227485 and IL-22RA1 rs3795299 may be associated with the development of PE in Chinese Han population. However, further validation is required in other populations, as well as an evaluation of the association of other SNPs in IL-22 and IL-22RA1 with PE.

show abstract

New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis

Abstract: The new cut-off values for the sFlt-1/PlGF ratio adjusted by the gestational age at clinical presentation can be used to rule out PE at obstetric triage and to predict imminent delivery with better accuracy than the cutpoint currently accepted.

Cited by 57 publications

References 2 publications

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants

Impact of IL‐22 and IL‐22 receptor alpha 1 polymorphisms on preeclampsia risk in Chinese Han women

Contact Info

Product

Resources

About